PATIENT STORIES: THE USE OF NOVEL ANTI-FIBROTICS, PIRFENIDONE AND NINTEDANIB, IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS, IPF

被引：0
|
作者：
Enston-Newall, S. [1 ]
机构：
[1] Cardiff Univ, Cardiff, S Glam, Wales
来源：
THORAX | 2017年 / 72卷
关键词：
D O I：
10.1136/thoraxjnl-2017-210983.443
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M21
引用
收藏
页码：A247 / A248
页数：2
相关论文
共 50 条
  • [31] Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
    Colin H. Holtze
    Elizabeth A. Freiheit
    Susan L. Limb
    John L. Stauffer
    Karina Raimundo
    Wayne T. Pan
    Kevin R. Flaherty
    Hyun J. Kim
    Respiratory Research, 21
  • [32] Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
    James Patrick Finnerty
    Aravind Ponnuswamy
    Prosjenjit Dutta
    Ammar Abdelaziz
    Hafiz Kamil
    BMC Pulmonary Medicine, 21
  • [33] South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
    Barratt, Shaney L.
    Mulholland, Sarah
    Al Jbour, Khaled
    Steer, Henry
    Gutsche, Markus
    Foley, Noeleen
    Srivastava, Rajiv
    Sharp, Charles
    Adamali, Huzaifa I.
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [34] Gastrointestinal Adverse Events with Nintedanib with Add-On Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (IPF): Further Analyses of INJOURNEY
    Vancheri, C.
    Kreuter, M.
    Richeldi, L.
    Ryerson, C. J.
    Valeyre, D.
    Grutters, J. C.
    Stansen, W.
    Quaresma, M.
    Stowasser, S.
    Wuyts, W. A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [35] Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry
    Holtze, Colin H.
    Freiheit, Elizabeth A.
    Limb, Susan L.
    Stauffer, John L.
    Raimundo, Karina
    Pan, Wayne T.
    Flaherty, Kevin R.
    Kim, Hyun J.
    RESPIRATORY RESEARCH, 2020, 21 (01)
  • [36] Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis
    Finnerty, James Patrick
    Ponnuswamy, Aravind
    Dutta, Prosjenjit
    Abdelaziz, Ammar
    Kamil, Hafiz
    BMC PULMONARY MEDICINE, 2021, 21 (01)
  • [37] Nintedanib & Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) in King Abdulaziz Medical City (KAMC), Riyadh - Real Life Data
    Khan, A. M.
    Al-Jahdali, H. H.
    Alharbi, A. S.
    Rajendram, R.
    Obaidi, M.
    Alghamdi, B.
    Hassan, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [38] Real World Experience of Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis
    Mulholland, S. A.
    Al Jbour, K.
    Steer, H.
    Gutsche, M.
    Foley, N.
    Srivastava, R.
    Sharp, C.
    Adamali, H. I.
    Barratt, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [39] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
    Siri T. Lehtonen
    Anniina Veijola
    Henna Karvonen
    Elisa Lappi-Blanco
    Raija Sormunen
    Saara Korpela
    Ulrika Zagai
    Magnus C. Sköld
    Riitta Kaarteenaho
    Respiratory Research, 17
  • [40] Acute Exacerbation of Idiopathic Pulmonary Fibrosis With Pirfenidone and Nintedanib: A Friend or Foe
    Kaushal, Mohit
    Talwar, Dhruv
    Prajapat, Deepak
    Kumar, Sunil
    Acharya, Sourya
    Talwar, Deepak
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (02)
12345